FRIENDSWOOD, Texas / Jul 17, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned a second consecutive Arizona Top Workplace award from AZ Central, the digital home of The Arizona Republic newspaper.
“We are thrilled to have once again been recognized as a Top Workplace in Arizona; this award is especially meaningful as it is based on feedback from our employees and is a testament to our unique workplace culture,” said Derek Maetzold, president and chief executive officer at Castle Biosciences. “We are truly grateful for our exceptional Castle team members who believe in our vision of keeping people first and show up each day, passionate about improving patient care.”
Top Workplace designations are garnered solely through anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey measures 15 culture drivers that are indicative of successful organizations, such as alignment, execution and connection. Castle’s survey participation rate of 89% and employee engagement score of 81% were both well above the benchmark averages of 59% and 53%, respectively, for other similar healthcare companies participating in the Top Workplaces program.
Earlier this year, Castle also earned five Top Workplaces Culture Excellence Awards for continued excellence in the following areas of its workplace culture:
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
About Energage
Making the world a better place to work together.™
Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 16 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit energage.com or topworkplaces.com.
Last Trade: | US$21.51 |
Daily Change: | 0.25 1.18 |
Daily Volume: | 445,939 |
Market Cap: | US$602.500M |
February 27, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load